RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Neoline-1 (ventilator)

Product
Developers: Technical device
Date of the premiere of the system: October 2024
Branches: Pharmaceuticals, Medicine, Healthcare

Content

History

2024: Product Announcement

In October 2024, the Tekhpribor company, which is part of the Radioelectronic Technologies concern of the Rostec state corporation, received a registration certificate for the first domestic artificial lung ventilation device for newborns Neoline-1. The innovative equipment is designed for non-invasive respiratory support and inhalation with an oxygen-air mixture of newborns and children under one year old.

According to Rostec, the Neoline-1 apparatus is designed for use in maternity wards, resuscitation and intensive care units of children's hospitals and perinatal centers. The device has the function of controlling the saturation and pulse rate of a small patient, which makes it possible to ensure the most effective and safe treatment.

The first Russian artificial non-invasive lung ventilation device for newborns has been released

Aleksey Melnikov, Deputy General Director for the Development of Civilian Products and National Projects of KRET, stressed that Neoline-1 is being launched on the market in the maximum configuration. The expert class apparatus has wide functionality, including the determination of respiratory rate in any operating conditions, automatic flow control and the ability to adjust the rate of pressure increase.

The development of Neoline-1 was carried out within the framework of the import substitution program at the engineering and innovation center of the Tekhpribor enterprise. When creating the device, additive technologies were actively used that allow printing prototypes of parts on industrial 3D printers, which significantly reduced the time for product development.

In terms of technical characteristics, the Russian apparatus is not inferior to foreign counterparts, which opens up prospects for its export. By October 2024, Neoline-1 is preparing for testing in medical institutions. The start of sales is scheduled for 2025.[1]

Notes